China Alliance for Rare Disease Holds Inaugural Meeting
BEIJING, Oct. 31, 2018
BEIJING, Oct. 31, 2018 /PRNewswire/ -- CANbridge Pharmaceutical Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that it was named one of four Deputy Director Generals at the inaugural meeting of the China Alliance for Rare Disease (CARD), held in Beijing, China on October 24th.CANbridge is the only industry representative appointed to such a position. The formal launch of the Alliance, which is comprised of stakeholders from many leading national institutions, marks a watershed moment in China's progress toward building an environment conducive to the development of rare disease therapies and treatment access in China.
"This Alliance brings together rare disease experts, patients, drug developers and reimbursement specialists to speak as one voice, and to push forward policy changes and regulatory reforms that will support access to rare disease treatments in China," said James Xue, PhD, Chairman and CEO, CANbridge Pharmaceutical. "We are deeply honored to be the only pharmaceutical company appointed to the Deputy Director General position, and along with the other members of the Alliance, will contribute a much-needed industry perspective to the evolution of the Chinese rare disease ecosystem, in keeping with our mission."
"Under the leadership of the China Alliance for Rare Disease, the development of China's rare disease industry will be accelerated through collaboration," said Yupei Zhao,MD, Director General of CARD and President of Peking Union Hospital. "China will become an active player in the global rare disease research community, formulating and promoting a model that is unique to China."
About the China Alliance for Rare Disease
The China Alliance for Rare Disease (CARD) is a national, non-profit, cooperative exchange platform for rare disease, approved by the national health authority, and supported by Peking Union Medical College Hospital, PhiRDA, the Chinese Medical Association, the Chinese Hospital Association and the Chinese Research Hospital Association, as well as multiple universities, scientific research institutes and enterprises.
The Alliance aims to meet the growing needs of the Chinese people for a better, healthier life, particularly those who suffer from rare diseases, by promoting the development of a rare disease biomedical industry, as well as improving standardized rare disease diagnosis, treatment and education for patients and the medical community in China. The Alliance is focused on creating patient-centered solutions, through bringing together multiple stakeholders, to build a robust and efficient rare disease infrastructure in China that can improve the quality of life for patients and their families.
About CANbridge Pharmaceutical Inc.
CANbridge Pharmaceutical Inc. is a China-based bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region.
CANbridge has been widely recognized as a leader in orphan diseases in China, and has a partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare diseases. CANbridge also has exclusive rights to develop and commercialize Puma Biotechnology's NERLYNX® (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China); a license with Apogenix to develop and commercialize APG101 in greater China; a license (ex-North America) to develop and commercialize AVEO Oncology's ErbB3 (HER3) inhibitory antibody candidate AV203 and an agreement with EUSA Pharma to commercialize Caphosol® for the prevention and treatment of oral mucositis caused by cancer treatments, for which it has received approval in China.
For more on CANbridge Pharmaceutical Inc., please go to www.canbridgepharma.com.
CANbridge Pharmaceutical Inc.
SOURCE CANbridge Pharmaceutical Inc.